The purpose of the Idiopathic Granulomatous Mastitis (IGM) Registry is to collect data on a large cohort of patients across multiple institutions to identify the most efficacious ways to treat this condition. The IGM Registry uses a short data-entry form housed in the Society’s HIPAA-compliant Mastery of Breast Surgery® Program, a member benefit.
Simple Steps to Join Mastery & Participate
- Upon requesting your account, please allow for up to 2 business days to receive your welcome email. This welcome email will contain your credentials for logging into masterybreastsurgeons.org.
- The Mastery Program will walk first-time users through the License and Business Agreements.
- Enter new patients on the "Add Patient" page, or choose an existing patient in the "My Patient List" dropdown.
- Click on the "Granulomatous Mastitis Registry" button and complete the brief data entry form.
Timeframe and Expectations
Participants will enter data on medical and surgical management, comprised initial data and 1-, 3-, 6-, and 12-month follow-up data. Participants will receive quarterly reminder emails. Results will be released to the membership after the completion of data collection and analysis.
Frequently Asked Questions
Idiopathic granulomatous mastitis (IGM) is an uncommon inflammatory condition that requires specialized care. Etiology is unclear and medical and surgical management is complicated. There is a paucity of high-quality literature on its treatment. These patients often get discussed on the ASBRS Forums with mixed recommendations. It is a problem the membership has to treat without consensus on the best treatments. The purpose of this registry trial to be able to collect data on a large cohort of patients across multiple institutions to identify the most efficacious ways to treat this condition.
• To collect prospective multi-institutional data on the most common diagnosis, medical and surgical treatments for IGM
• To identify which patients will have a high chance of success with medical management and which ones will likely need surgery
• To compare the best initial medical management strategies for IGM with shortest time to resolution
1. Gautham, I., et al., Cystic neutrophilic granulomatous mastitis: The Cleveland Clinic experience with diagnosis and management. Breast J, 2019. 25(1): p. 80-85.
2. Pluguez-Turull, C.W., et al., Idiopathic Granulomatous Mastitis: Manifestations at Multimodality Imaging and Pitfalls. Radiographics, 2018. 38(2): p. 330-356.
3. Barreto, D.S., et al., Granulomatous mastitis: etiology, imaging, pathology, treatment, and clinical findings. Breast Cancer Res Treat, 2018. 171(3): p. 527-534.
4. Lai, E.C., et al., The role of conservative treatment in idiopathic granulomatous mastitis. Breast J, 2005. 11(6): p. 454-6.
5. Prasad, S., et al., Idiopathic granulomatous mastitis: an institutional experience. Turk J Surg, 2017. 33(2): p. 100-103.
6. Uysal, E., et al., Factors related to recurrence of idiopathic granulomatous mastitis: what do we learn from a multicentre study? ANZ J Surg, 2018. 88(6): p. 635-639.
7. Chirappapha, P., et al., Idiopathic granulomatous mastitis: A retrospective cohort study between 44 patients with different treatment modalities. Ann Med Surg (Lond), 2018. 36: p. 162-167.
Yes. Institutional Review board exemption from "federal regulations" for "human research" will be obtained because all data will be de-identified.
Sarah Blair, MD, UC San Diego Health
Nimmi Kapoor, MD, Cedars Sinai
Katrina B. Mitchell, MD, Ridley Tree Cancer
Linda Smith, MD, Albuquerque